ML-193 (CID 1261822) is a potent and selective antagonist ofGPR55, with anIC₅₀of 221 nM. ML-193 shows more than 27-fold selectivity forGPR55overGPR35,CB1andCB2. ML-193 can improve the motor and the sensorimotor deficits of Parkinson’s disease (PD) rats^[1][2][3].

IC50: 221 nM (GPR55)^[1]

ML-193 (0.01-100 μM; pretreated for 15 min) inhibits β-arrestin trafficking induced by L-α-lysophophosphatidylinositol (LPI, 10 μM) and ML186 (1 μM) with IC₅₀s of 0.22 μM and 0.12 μM, respectively^[2].
ML-193 (0.01-10 μM; pretreated for 30 min) decreases the LPI-mediated ERK1/2 phosphorylation, with an IC₅₀of 0.2 μM in U2OS cells^[2].
ML-193 (5 μM; pretreated for 30 min) attenuates the GPR55 agonists induced increases in hNSCs proliferation rates^[4].
ML-193 (5 μM; 10 d) attenuates the ML184-induced increases in hNSCs differentiation^[4].

ML193 (1 and 5 μg/rat; intra-striatal at a rate of 1 μL/min) attenuates sensorimotor deficits and slip steps, increases motor coordination in PD rats^[3].

527.59

Solid

C₂₈H₂₅N₅O₄S

713121-80-3

Room temperature in continental US; may vary elsewhere.